DE-THE-LYCRA-COMPANY
27.8.2024 11:01:33 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel and personal care industries, announced today that it is showcasing its sustainable offerings and more at Intertextile Shanghai from August 27 to 29. The LYCRA Company Pavilion in Hall 4.1 (Booth E56) features 931 square meters of exhibit space and 25 co-exhibitors united under the theme “Accelerating Our Journey to Decarbonization.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827097449/en/
The LYCRA Company is showcasing its sustainable offerings and more at Intertextile Shanghai from August 27 to 29. Its pavilion in Hall 4.1 (Booth E56) features 25 co-exhibitors united under the theme “Accelerating Our Journey to Decarbonization.” Visitors to the Econogy Hub (Hall 5.1, Booth A36) will discover through an immersive experience in a replica cornfield how bio-derived LYCRA® fiber made with QIRA® can help accelerate decarbonization in the fashion industry. (Photo: Business Wire)
The LYCRA Company will highlight products designed to meet consumer needs and help reduce the environmental impact of apparel products:
- Bio-derived LYCRA® fiber made with QIRA®, the industry’s first renewable spandex available at scale, will launch in the first half of 2025. Made from annually grown field corn, it's expected to reduce the carbon footprint of LYCRA® fiber by up to 44 percent* while delivering equivalent performance to the original fiber. Visitors to the Econogy Hub (Hall 5.1, Booth A36) will discover through an immersive experience in a replica cornfield how this patented innovation can help accelerate decarbonization in the fashion industry.
- LYCRA® FiT400™ fiber is a unique bicomponent fiber engineered to optimize the comfort and performance of knits while delivering a durable, soft hand feel, all-day stretch, long-lasting fit, and cooling comfort. This Global Recycled Standard-certified fiber contains 60% recycled PET and 14.4% bio-derived resources.
- COOLMAX® EcoMade fiber made from 100% textile waste delivers cool and dry comfort to various garment types, while THERMOLITE® EcoMade fiber made from 100% textile waste adds lightweight warmth.
“We are thrilled to showcase our sustainable solutions at Intertextile that will help our customers reduce their carbon footprint and support their sustainability goals,” said Jason Wang, vice president, Asia. “We look forward to helping attendees find the consumer-driven, market-relevant branded solutions they need to take their business to the next level.”
The LYCRA Company will also showcase LYCRA® ADAPTIV fiber, one of the company’s fastest-growing products. Brands and retailers worldwide appreciate how it enables inclusive sizing and delivers a second-skin fit, enhanced comfort in motion, and greater functionality to activewear, intimate apparel, denim, and more. Regina Miracle, a leading garment maker and a key value chain partner of The LYCRA Company, will exhibit garment samples.
The booth will also feature garment samples of new LYCRA FitSense® denim technology, a targeted shaping innovation for stretch denim to deliver a customizable fit to different body types and shapes, a breakthrough for the industry launched this year. Through a combination of fiber, fabric, and garment processing technologies, this discreet and invisible solution retains the authentic denim look and feel that consumers desire.
To learn more about The LYCRA Company’s latest innovations and commitment to a more sustainable future, visit Intertextile Booth E56 in Hall 4.1 and Booth A36 in Hall 5.1, or visit this website.
*Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
LYCRA®, LYCRA® FiT400™, LYCRA FitSense®, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.
QIRA® is a trademark of Qore®.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827097449/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom